These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35020817)

  • 21. The year in cardiovascular medicine 2021: diabetes and metabolic disorders.
    Cosentino F; Bhatt DL; Marx N; Verma S
    Eur Heart J; 2022 Jan; 43(4):263-270. PubMed ID: 34974614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation.
    Arnold MJ; Buelt A
    Am Fam Physician; 2022 Jun; 105(6):675-677. PubMed ID: 35704807
    [No Abstract]   [Full Text] [Related]  

  • 23. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
    Karagiannis T; Tsapas A; Athanasiadou E; Avgerinos I; Liakos A; Matthews DR; Bekiari E
    Diabetes Res Clin Pract; 2021 Apr; 174():108737. PubMed ID: 33705820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome.
    Premji R; Nylen ES; Naser N; Gandhi S; Burman KD; Sen S
    Metab Syndr Relat Disord; 2022 Aug; 20(6):321-328. PubMed ID: 35452324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research digest: pioneering an oral GLP-1 receptor agonist.
    Atkinson MA; Powers AC
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):897. PubMed ID: 31748168
    [No Abstract]   [Full Text] [Related]  

  • 27. In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs.
    Tanner M
    Ann Intern Med; 2021 Jun; 174(6):JC67. PubMed ID: 34058114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
    Meade LT; Mannka ML
    Ann Pharmacother; 2019 Nov; 53(11):1111-1116. PubMed ID: 31215219
    [No Abstract]   [Full Text] [Related]  

  • 30. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization.
    Shepard BD; Ecelbarger CM
    Semin Nephrol; 2021 Jul; 41(4):331-348. PubMed ID: 34715963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A practical review of diabetes mellitus type 2 treatment in primary care.
    Call JT; Cortés P; Harris DM
    Rom J Intern Med; 2022 Mar; 60(1):14-23. PubMed ID: 34333891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Laiteerapong N; Alexander J; Philipson L; Winn AN; Huang ES
    Ann Intern Med; 2023 Apr; 176(4):eL230007. PubMed ID: 37068291
    [No Abstract]   [Full Text] [Related]  

  • 34. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 35. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
    Scheen AJ
    Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Hanna C; Pettersen K; Pedley N
    Ann Intern Med; 2023 Apr; 176(4):eL230006. PubMed ID: 37068293
    [No Abstract]   [Full Text] [Related]  

  • 37. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Carriazo S; Ortiz A; Fernandez-Fernandez B
    Ann Intern Med; 2023 Apr; 176(4):eL230005. PubMed ID: 37068289
    [No Abstract]   [Full Text] [Related]  

  • 38. Time to Follow the Evidence: Glycemic Control and Cardiovascular Benefits of New Diabetes Medications.
    Draznin B; Hirsch IB
    Am J Med; 2021 Apr; 134(4):420-422. PubMed ID: 33434557
    [No Abstract]   [Full Text] [Related]  

  • 39. [Indications of antidiabetic drugs beyond glucose control].
    Hartmann NK; Lehrke M
    MMW Fortschr Med; 2023 Mar; 165(5):42-49. PubMed ID: 36894856
    [No Abstract]   [Full Text] [Related]  

  • 40. GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms.
    Gómez-Peralta F; Abreu C; Rizzo M
    J Diabetes Complications; 2023 Aug; 37(8):108553. PubMed ID: 37385011
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.